Lead sponsor
MetaCure (USA), Inc.
1 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
1
Trials led
0
Active
20
Total enrollment
13
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Not applicable
1
Trials by status
Terminated
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist TherapyBMI ≤40not applicableTerminated20